-
EP3303391
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3303391
| EP3303391 - METHODS AND PHARMACEUTICAL COMPOSITIONS (NTSR1 INHIBITORS) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.03.2021 Database last updated on 09.09.2024 | |
| Former | Examination is in progress Status updated on 21.09.2018 | ||
| Former | Request for examination was made Status updated on 09.03.2018 | ||
| Former | The international publication has been made Status updated on 02.12.2016 | Most recent event Tooltip | 26.03.2021 | Application deemed to be withdrawn | published on 28.04.2021 [2021/17] | Applicant(s) | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris / FR | For all designated states Université Paris Descartes 12, rue de l'Ecole de Médecine 75006 Paris / FR | [2018/15] | Inventor(s) | 01 /
FORGEZ, Patricia Inserm UMRS 1007 - Université Paris Descartes 45 rue des Saints-Pères 75270 Paris cedex 06 / FR | 02 /
WU, Zherui Inserm UMRS 1007 - Université Paris Descartes 45 rue des Saints-Pères 75270 Paris cedex 06 / FR | [2018/15] | Representative(s) | Inserm Transfert PariSanté Campus 10 rue d'Oradour-sur-Glane 75015 Paris / FR | [N/P] |
| Former [2018/15] | Collin, Matthieu Inserm-Transfert Paris Biopark 7, rue Watt 75013 Paris / FR | Application number, filing date | 16727366.3 | 26.05.2016 | [2018/15] | WO2016EP61909 | Priority number, date | EP20150305784 | 26.05.2015 Original published format: EP 15305784 | [2018/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016189091 | Date: | 01.12.2016 | Language: | EN | [2016/48] | Type: | A1 Application with search report | No.: | EP3303391 | Date: | 11.04.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.12.2016 takes the place of the publication of the European patent application. | [2018/15] | Search report(s) | International search report - published on: | EP | 01.12.2016 | Classification | IPC: | C07K16/28, C07K16/30, A61K39/00 | [2018/15] | CPC: |
A61P35/00 (EP,US);
C07K16/286 (US);
A61K31/44 (EP,US);
A61K31/517 (EP,US);
A61K47/6849 (US);
C07K16/26 (EP,US);
C07K16/303 (US);
C12N15/1138 (US);
A61K2039/505 (US);
C07K2317/21 (US);
C07K2317/24 (US);
C07K2317/732 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/15] | Title | German: | VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN (NTSR1-INHIBITOREN) ZUR BEHANDLUNG VON HEPATOZELLULÄREN KARZINOMEN | [2018/15] | English: | METHODS AND PHARMACEUTICAL COMPOSITIONS (NTSR1 INHIBITORS) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS | [2018/15] | French: | PROCÉDÉS ET COMPOSITIONS PHARMACEUTIQUES (INHIBITEURS DE NTSR1) POUR LE TRAITEMENT DE CARCINOMES HÉPATOCELLULAIRES | [2018/15] | Entry into regional phase | 21.11.2017 | National basic fee paid | 21.11.2017 | Designation fee(s) paid | 21.11.2017 | Examination fee paid | Examination procedure | 21.11.2017 | Amendment by applicant (claims and/or description) | 21.11.2017 | Examination requested [2018/15] | 21.11.2017 | Date on which the examining division has become responsible | 25.09.2018 | Despatch of a communication from the examining division (Time limit: M04) | 15.01.2019 | Reply to a communication from the examining division | 20.05.2019 | Despatch of a communication from the examining division (Time limit: M04) | 02.09.2019 | Reply to a communication from the examining division | 20.05.2020 | Despatch of a communication from the examining division (Time limit: M06) | 01.12.2020 | Application deemed to be withdrawn, date of legal effect [2021/17] | 22.12.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/17] | Fees paid | Renewal fee | 25.05.2018 | Renewal fee patent year 03 | 21.05.2019 | Renewal fee patent year 04 | 17.03.2020 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]US2005112678 (YANG JIANXIN [US]) [X] 1,3-9 * See claims 7-16, 40-48; paragraphs 270-320 * [I] 2; | [I]WO2009127619 (INST NAT SANTE RECH MED [FR], et al) [I] 1-9* See page 7, line 1- page 10, line 3; Claims 1-11 * | by applicant | US4486414 | US4816567 | US4816444 | US4879278 | US4978744 | EP0404097 | US4986988 | US5076973 | US5138036 | WO9308829 | WO9311161 | US5410024 | US5504191 | US5521284 | US5530097 | US5554725 | US5599902 | US5635483 | US5663149 | US5665860 | US5780588 | WO9932619 | US5981732 | US6034065 | US6046321 | US6075181 | US6107091 | US6150584 | WO0136646 | US6239104 | WO0168836 | US6323315 | US6365354 | US6410323 | WO02088172 | US6506559 | US2003083263 | US6566135 | US6566131 | US6573099 | WO2004010957 | US6884869 | US6982321 | WO2006064136 | US7087409 | - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855 | - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525 | - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329 | - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596 | - VASWANI; HAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., (1998), vol. 1, pages 105 - 115 | - HARRIS, BIOCHEM. SOC. TRANSACTIONS, (1995), vol. 23, pages 1035 - 1038 | - HURLE; GROSS, CURR. OP. BIOTECH., (1994), vol. 5, pages 428 - 433 | - HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381 | - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581 | - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77 | - BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, no. L, pages 86 - 95 | - VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL., (2001), vol. 5, pages 368 - 74 | - LI ET AL., PROC. NATL. ACAD. SCI. USA, (2006), vol. 103, pages 3557 - 3562 | - MILSTEIN ET AL., NATURE, (1983), vol. 305, pages 537 - 39 | - TRAUNECKER ET AL., EMBO J., (1991), vol. 10, pages 3655 - 59 |